To mark the 30th anniversary of The American Journal of Managed Care, each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The November issue features a conversation with Laurie C. Zephyrin, MD, MPH, MBA, senior vice president for achieving equitable outcomes at the Commonwealth Fund. This interview has been edited for length and clarity.

Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival.

Total neoadjuvant treatment achieved high complete response and organ preservation rates in patients with stage I rectal cancer, according to a new study.

Foster and kinship care children formed stronger bonds with carers, but relationship quality didn’t predict later emotional outcomes, a study finds.

Cefdinir is linked to nearly double the outpatient uncomplicated UTI treatment failure of cephalexin, with higher recurrence and increased resistance to other cephalosporins.

The author, from Reimagine Care, discusses how AI can enhance oncology care by prioritizing patient needs, fostering trust, and streamlining communication through familiar text-based support for all ages.

AI is poised to transform oncology with innovative tools enhancing diagnosis, treatment, and clinical trials, despite some wariness from clinicians and patients.

A Stakeholder Interchange convened in Los Angeles, California, by The American Journal of Managed Care explores the treatment landscape for relapsed/refractory multiple myeloma, focusing on the challenges of bringing bispecific antibodies to patients in an outpatient setting.

Utilizing the Health Insurance Disparities Index for assessment, the authors found that New York’s Medicaid health maintenance organizations (HMOs) outperformed Medicaid HMOs nationally in addressing health care disparities from 2019 to 2023.

HHS has initiated removal of black box warnings on hormone replacement therapy, citing its advantages to women's health, but also drawing pushback.

The trial did not meet its primary end point for reducing plaque progression.

New findings reveal high rates of depression, anxiety, and sleep issues in individuals with psoriatic arthritis and palmoplantar psoriasis.

In this investigation, the authors evaluated the impact of a voluntary transition to risk-based contracts under Medicare Advantage on health care use.

A white paper explores how biomarker testing enhances patient outcomes and what barriers prevent access in several common cancers.

Delgocitinib has emerged as a promising treatment for CHE, addressing unmet needs and enhancing understanding of this complex condition, notes Raj Chovatiya, MD, PhD, MSCI.

Higher dietary fiber intake was associated with a reduced risk of moderate to severe diarrhea up to 2 years after diagnosis.

Combining 3 standard therapies into a single pill improved outcomes for adults with heart failure with reduced ejection fraction.

New research suggests stress cardiac MRI could help diagnose angina and improve quality of life for patients whose arteries appear clear on angiography.

Eosinophilia serves as a significant biomarker for predicting immune-related adverse events in NSCLC patients treated with immune checkpoint inhibitors.

Only 4% of NIH prevention projects target health disparities, revealing a major gap between equity research and real-world implementation.

Experts discuss the urgent need for equitable access to cancer care, addressing barriers in treatment delivery and the importance of personalized medicine.

Experts discuss the intersection of innovation, affordability, and access in cancer care, focusing on multiple myeloma and NSCLC advancements.

In a phase 3 trial, the investigational oral PCSK9 inhibitor enlicitide reduced LDL cholesterol by nearly 60% in adults with or at risk for ASCVD.

Experts at AHA 2025 outlined how digital tools, inclusive trials, and safer deprescribing can reshape cardiovascular care for aging adults.

Gefurulimab shows significant improvements in myasthenia gravis (MG) symptoms, offering a convenient self-administered treatment option for patients.